RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.63) per share. This is unchanged from the same period last year.
AbCellera Announces That The U.S. Patent Trial And Appeal Board Has Denied Berkeley Lights’ Request For Rehearing
PTAB rejects request by Berkeley Lights to reconsider its decision denying Berkeley's argument that AbCellera's U.S. patent is invalid
AbCellera (NASDAQ:ABCL) announced that the United States Patent and
